Neuroanatomical Predictors of Response to Donepezil Therapy in Patients With Dementia

Hippocampal Shape Analysis of Alzheimer Disease Based on Machine Learning Methods

“…A third method used the surface modeling methods to map hippocampal shape abnormality in AD. Such a surface-based method 17,19,20,42,43 allows us to detect more subtle changes in the hippocampus in comparison with the VBM and region of interest-based methods. Using a 3D parametric mesh model, Thompson et al 17 found that the hippocampal atrophic rates were faster in patients with AD than in the control subjects.…”

“…Using a 3D parametric mesh model, Thompson et al 17 found that the hippocampal atrophic rates were faster in patients with AD than in the control subjects. Csernansky et al 19,20 used the highdimensional brain mapping methods to detect an AD-specific pattern in the hippocampus that was not found through the volume methods. In this study, we used surface modeling to characterize the hippocampal shape changes in AD.…”

“…Many recent studies [17][18][19][20] have focused on characterizing regional abnormalities of hippocampal atrophy using computational anatomy mapping and statistical analysis methods. These regional surface measures of the hippocampus can provide more subtle indexes compared with the volume and tissue concentration differences in discriminating between patients with AD and healthy control subjects.…”

“…They were used not only to distinguish subjects with very mild AD from nondemented subjects 18 but also to track the progression of AD in drug trials. 19 Usually, regional shape abnormalities of the hippocampus are statistically analyzed by univariate methods based on some previous hypotheses. However, statistical comparisons using these approaches had limitations in identifying subtle differences between 2 populations.…”

Clinical Profile of Alzheimer’s Disease Non-Responder Patient

“…Recently, the development of neuro-morphometric measures of regional blood flow and also brain metabolism provided a new possible biomarker of the AD pathologic process. In particular, volumetric analysis of different brain regions showed that hippocampal volume loss is present in patients with mild AD, and the progression of volume loss parallels the worsening of clinical symptoms, and may also be used to predict to the pharmacological response of patients (Csernansky et al, 2005). Moreover, during AD neuro-psychiatric symptoms are usually persistent, although with variable intensity, and can also be resistant to treatment (Ryu et al, 2005).…”